Sanofi (ETR: SNW)
Germany
· Delayed Price · Currency is EUR
91.16
-0.11 (-0.12%)
Dec 20, 2024, 5:35 PM CET
Sanofi Revenue
Sanofi had revenue of 14.16B EUR in the quarter ending September 30, 2024, with 11.49% growth. This brings the company's revenue in the last twelve months to 48.45B, up 6.01% year-over-year. In the year 2023, Sanofi had annual revenue of 46.03B with 1.42% growth.
Revenue (ttm)
48.45B
Revenue Growth
+6.01%
P/S Ratio
n/a
Revenue / Employee
562.74K
Employees
86,088
Market Cap
114.43B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.03B | 644.00M | 1.42% |
Dec 31, 2022 | 45.39B | 6.21B | 15.86% |
Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSanofi News
- 1 day ago - Sanofi to buy China rights to Cytokinetics lead asset - Seeking Alpha
- 1 day ago - Cytokinetics Inc (CYTK) Announces Sanofi's Acquisition of Aficamten Rights in Greater China - GuruFocus
- 2 days ago - Presse release: Jean-Paul Kress to join Sanofi's Board of Directors - GlobeNewsWire
- 3 days ago - Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases - Benzinga
- 3 days ago - Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study - GuruFocus
- 4 days ago - Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's - Investopedia
- 4 days ago - Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment - The Wall Street Journal
- 4 days ago - Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment - WSJ